Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Del Fabro

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Oncogenesis|January 22, 2022
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironmentCesarina Giallongo, Ilaria Dulcamare, Daniele Tibullo, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Journal of Clinical Medicine|June 29, 2019
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma NetworkConcetta Conticello, Alessandra Romano, Vittorio Del Fabro, et al.
Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Oncogenesis|January 22, 2022
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironmentCesarina Giallongo, Ilaria Dulcamare, Daniele Tibullo, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Journal of Clinical Medicine|June 29, 2019
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma NetworkConcetta Conticello, Alessandra Romano, Vittorio Del Fabro, et al.
Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Pageof 4